Cargando…

No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer

BACKGROUND: Studies over the past 10 years strongly support an association between skeletal muscle mass (SMM) depletion and outcome in metastatic colorectal cancer (mCRC). Factors influencing SMM changes over time are, however, poorly studied. We analyzed the impact of SMM on overall survival and ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antoun, Sami, Bayar, Mohamed Amine, Dyevre, Valérie, Lanoy, Emilie, Smolenschi, Cristina, Ducreux, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714393/ https://www.ncbi.nlm.nih.gov/pubmed/31462288 http://dx.doi.org/10.1186/s12885-019-6086-2

Ejemplares similares

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)

Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
por: Ducreux, Michel
Publicado: (2009)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Skeletal muscle mass and adipose tissue alteration in critically ill patients
por: Dusseaux, Marie Mélody, et al.
Publicado: (2019)

Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy
por: Nagai, Takashi, et al.
Publicado: (2019)

Role of Epidural Analgesia within an ERAS Program after Laparoscopic Colorectal Surgery: A Review and Meta-Analysis of Randomised Controlled Studies
por: Borzellino, Giuseppe, et al.
Publicado: (2016)

Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
por: Cartry, Jérôme, et al.
Publicado: (2023)

Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
por: Kurk, Sophie, et al.
Publicado: (2019)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients
por: Kurk, Sophie A., et al.
Publicado: (2018)

Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients
por: Kurk, Sophie A, et al.
Publicado: (2019)

Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer
por: Toumazis, Iakovos, et al.
Publicado: (2017)

The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-Line Chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2019)

Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
por: Thivat, Emilie, et al.
Publicado: (2010)

Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer
por: Fisch, Michael J, et al.
Publicado: (2020)

Associations of pre‐existing co‐morbidities with skeletal muscle mass and radiodensity in patients with non‐metastatic colorectal cancer
por: Xiao, Jingjie, et al.
Publicado: (2018)

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
por: de Takats, P. G., et al.
Publicado: (1994)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment
por: Antoun, Sami, et al.
Publicado: (2019)

Response to “Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer”
por: Daly, Louise E., et al.
Publicado: (2016)

Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases
por: de Haas, Robbert J., et al.
Publicado: (2010)

Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients
por: Deutsch, Eric, et al.
Publicado: (2016)

Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2003)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study
por: Maddalena, Chiara, et al.
Publicado: (2021)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Prolonged survival in metastatic colorectal cancer following chemotherapy
por: Paul, Doru, et al.
Publicado: (2014)

Use of perioperative chemotherapy in colorectal cancer metastatic to the liver
por: Symonds, Lynn K, et al.
Publicado: (2019)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss
por: McCarthy, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1btm4u0g58u2u72l7u9n937vmn